Condition 1: Mindfulness-based cognitive therapy(MBCT). Condition 2: Crohn's disease. Condition 3: Ulcerative colitis. Condition 4: Depression. Condition 5: Anxiety. Crohn's disease [regional enteritis] Ulcerative colitis Major depressive disorder, single episode, mild Anxiety disorder, unspecified
Conditions
Interventions
Intervention 1: Intervention group:These people receive mindfulness-based cognitive therapy in addition to their usual medical treatment.Mindfulness-based cognitive therapy (MBCT) is an evidence-based
Sponsors
Kashan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: - Having informed consent to participate in research - Age 18-60 years - Confirmed diagnosis of Crohn's disease (CD) or ulcerative colitis (UC) (by a physician) - Patients should be in the active phase of IBD disease (Mild to moderate, moderate to severe) , not in the remission ,that accompanied by a decrease in symptoms - In the Anxiety, Depression, Stress DASS-21 questionnaire, the individual's score on the depression scale of 10 or higher and / or on the anxiety scale of 8 or higher and / or on the stress scale of 15 or higher - Ability to do light exercise (for example, to lift arms above the head or bend knees) because part of the practices in the program require this movement - Able to commit to attend the eight sessions (participants should consider their personal circumstances to assess if this is practical and feasible for them) - To be able to commit to do home practice of up to 45 minutes daily over the 8 weeks of the study (this is a core component of the program) - No change of antidepressants (dose or type) within the last 3 months
Exclusion criteria
Exclusion criteria: - Major psychiatric illness.(The treatment for a major psychiatric illness may interfere with the program) - Active alcohol or drug dependency -Scheduled for major surgery in the next 3 months - Participation in a pharmacological study or psychological intervention study within the last 6 months or intention to participate in a pharmacological study during the duration of this study - Have recently (within the last 3 months) been prescribed antidepressants - Exacerbation of symptoms and need for change in IBD medication (dose or type) during the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Depression. Timepoint: Before the intervention, after the intervention. Method of measurement: This variable is measured by the depression, anxiety, stress questionnaire (DASS-21).;Anxiety. Timepoint: Before the intervention, after the intervention. Method of measurement: This variable is measured by the depression, anxiety, stress questionnaire (DASS-21).;Stress. Timepoint: Before the intervention, after the intervention. Method of measurement: This variable is measured by the depression, anxiety, stress Questionnaire (DASS-21).;Abdominal pain. Timepoint: Before the intervention, after the intervention. Method of measurement: This variable is measured by the McGill Pain Questionnaire.;Pain catastrophizing scale. Timepoint: Before the intervention, after the intervention. Method of measurement: This variable is measured by the Catastrophizing Pain Scale (PCS).;Dispositional mindfulness. Timepoint: Before the intervention, after the intervention. Method of measurement: This variable is measured by the mindful, attention, awareness scale (MAAS).;Disease activity. Timepoint: Before the intervention, after the intervention. Method of measurement: 1_Clinical index :Crohn's disease activity index (CDAI) and Simple clinical colitis activity index (SCCAI) 2_ Blood sampling from each individual to measure each of the following: 1:CBC (Red blood cell count M/MCL, white blood cell count K/MCL, hematocrit) 2: CRP (C reactive protein level in the blood Mg/L) 3: ESR ( Erythrocyte sedimentation rate per unit time mm/h) 4: Albumin g/dL.;Quality of life. Timepoint: Before the intervention, after the intervention. Method of measurement: This variable is measured by the short form of the disease-specific IBD quality of life questionnaire (IBDQ-9) | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSara Hosseinpoor
Kashan University of Medical Sciences
Outcome results
None listed